Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/58ada64b-1b10-41ca-9778-f29bad6ee5b2/

PANACEABIO

Panacea Biotec Limited
Chart
₹540.20
Latest Week 2026-06-05
HealthcareBiotechnologyLARGE
Snapshot 2026-06-07 · 0.0w · Fresh
0.16
OS Score
22.0%
Value
15.0%
Quality
74.0%
Momentum
5/9
F-Score
0.182
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
0 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
22.0%ile
P/S
5.2×
P/B
4.0×
FCF Yield
-0.011
EBITDA/EV
0.010
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
89.00000000
/100 — 1=cheapest
VC2 (Trending Value)
91.00000000
/100
VC3 (Buyback)
92.00000000
/100
Negative FCF yield (-1.1%) — the business is currently cash-consumptive. VC2 score of 91.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
15.0%ile
ROE
-0.006
ROA
-0.004
Net Margin
-0.008
Op Margin
-0.059
GPA
0.285
Current
1.47
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.144
Stability
5.100
lower=better
Accruals
-0.017
lower=better
5yr Consist
No
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
74.0%ile
6M Return
57.0%
12M Return
20.7%
12-1 Mom
-13.1%
Risk-Adj
-0.27
Vol 252d
47.9%
Vol 60d
117.5%
↑ Expanding
Max DD 12M
-29.1%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -13% signals a downtrend — price is moving against you. Near-term vol (117%) is expanding vs long-term (48%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.16
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 160 peers
Sector Value %ile
43.5%
Sector Quality %ile
13.7%
P/B z-score
-0.32
Sector Avg OS
43.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
NATCOPHARM NATCO Pharma Limited 98.0% 88.0% 87.0% 81.0%
UNIVPHOTO Universus Photo Imagings Limited 97.0% 86.0% 74.0% 94.0%
LINCOLN Lincoln Pharmaceuticals Limited 97.0% 88.0% 80.0% 81.0%
STAR Strides Pharma Science Limited 96.0% 73.0% 91.0% 91.0%
VENUSREM Venus Remedies Limited 96.0% 68.0% 94.0% 99.0%
HALEOSLABS Haleos Labs Limited 95.0% 82.0% 77.0% 81.0%
AUROPHARMA Aurobindo Pharma Limited 94.0% 71.0% 84.0% 87.0%
SPARC Sun Pharma Advanced Research Company Limited 93.0% 72.0% 86.0% 83.0%
Factor Interactions
Volatility Expanding
60-day vol (117%) significantly exceeds 252-day (48%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
28.5% avg (5 factors)
Quality
F
25.2% avg (7 factors)
Momentum
C
47.6% avg (4 factors)
Risk
D
36.8% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.160—1—
Value %ile0.220—1—
Quality %ile0.150—1—
Momentum %ile0.740—1—
F-Score5.000—0—
Confidence0.848—1—
Volatility0.479—1—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Sales
5.17
Price / Book
3.96
Price / Cash Flow
198.37
FCF Yield
-1.1%
EBITDA / EV
1.0%
Sales Yield (1/P·S)
0.1953
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
-0.6%
Return on Assets
-0.4%
Net Margin
-0.8%
Operating Margin
-5.9%
Gross Profit / Assets
Novy-Marx GPA
28.5%
Current Ratio
1.47
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.017
MomentumPrice trend strength over different horizons
6M Return
57.0%
12M Return
20.7%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-13.1%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.27
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
14.4%
Earnings Stability (CV)
Lower = more stable
5.100
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
5
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
89
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
91
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
92
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity